



## Insights Into Multiple Myeloma March, 2021

Chair: Rafael Fonseca, MD

### AGENDA

Time (PST)	Topic
5.00 PM – 5.15 PM (15 min)	<b>Introduction</b> <ul style="list-style-type: none"> <li>• Program overview</li> <li>• Baseline ARS questions</li> </ul>
5.15 PM – 6.20 PM (25-min presentation; 40-min discussion)	<b>Emerging Treatments for Relapsed/Refractory Multiple Myeloma</b> <ul style="list-style-type: none"> <li>• Overview of recent data           <ul style="list-style-type: none"> <li>– BCMA-targeting ADCs               <ul style="list-style-type: none"> <li>▪ Belantamab mafodotin (bela-maf)</li> <li>▪ MEDI2228</li> </ul> </li> <li>– Anti-BCMA CAR T-cell therapies               <ul style="list-style-type: none"> <li>▪ Idecabtagene vicleucel (ide-cel)</li> <li>▪ Ciltacabtagene autoleucel (cilta-cel)</li> </ul> </li> <li>– BCMA-targeting bispecific antibodies               <ul style="list-style-type: none"> <li>▪ Teclistamab</li> <li>▪ REGN5458</li> <li>▪ TNB-383B</li> <li>▪ AMG 701</li> </ul> </li> </ul> </li> <li>• Reaction and discussion</li> </ul>
6.20 PM – 6.30 PM (10 min)	<b>Key Takeaways and Meeting Evaluation</b>